Back

Semaglutide provides cardio-protection in anthracycline-treated non-hodgkin lymphoma: a propensity-matched real-world study

28 August 2026 (14:22 - 14:41)
Organised by: Logo
Congress Presentation Part of: Real-world evidence in cardio-oncology: what is it and what can it tell us? Cardio-Oncology ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Charalampos Filippatos

National & Kapodistrian University of Athens Medical School, Athens (Greece)

3 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on real-world evidence in cardio-oncology
Associate Professor P. Ameri (Genova, IT)
Slides Video
Presentation thumbnail
Upfront immune checkpoint inhibitors and long-term risk of major adverse cardiovascular events: a population-based propensity-matched cohort study
Doctor I. Nardi Agmon (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
Long-term outcomes of heart transplant recipients with a history of malignancy: a nationwide population-based cohort study
Professor J. Youn (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Real-world evidence in cardio-oncology: what is it and what can it tell us?
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 14:22 CET
You may be interested in
thumbnail
Congress Presentation
GLP-1 receptor agonists for anthracycline-associated cardiac outcomes: first meta-analytic evaluation in propensity-matched cohorts
30 August 2026
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
31 August 2025
thumbnail
Congress Presentation
Cardiovascular and non-cardiovascular adverse events in patients with hematologic malignacies treated with BTK inhibitors: a real-world analysis
2 September 2024
thumbnail
Congress Session
Evolving cardiovascular complications in cancer survivors: vascular and cardiometabolic risks
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources